Haleon Financials - Benzinga

Haleon PLC

HLNNYSE

Trade with Public

Trade with Public

$10.15

0.121.2%

Últ. Act.: Sep 1, 9:29 AM

Panorámica general Noticias Previsión de beneficios Precios objetivoFinanzasSentimiento Propiedad Dividendos Comparar Opciones Informe de acciones

Haleon Financials

Haleon (HLN) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Haleon H1 Adj. EPS $0.14 Up From $0.12 YoY, Sales $7.533B Beat $3.600B Estimate

Haleon (NYSE:HLN) reported quarterly earnings of $0.14 per share. This is a 16.67 percent increase over earnings of $0.12 per share from the same period last year. The company reported quarterly sales of $7.533 billion

Benzinga Newsdesk

Sensodyne Toothpaste Maker Haleon Expects Profit To Be Weighted Towards Second Half Of 2025

Haleon posted £11.23B in FY24 revenue, with 5% organic growth. 2025 guidance expects 4-6% organic growth, with profit gains weighted to the second half.

Vandana Singh

PRO
Haleon Sees FY25 Organic Revenue Growth Of 4%-6%, Allocates GBP500M For Share Buybacks

Benzinga Newsdesk

PRO
Haleon FY Adjusted EPS GBp17.9 Up From GBp17.3 YoY, Sales GBP11.2B Down From GBP11.3B YoY

Benzinga Newsdesk

Earnings Scheduled For February 27, 2025

Benzinga Insights

Dr Reddy's Laboratories Q3 Earnings: Double-Digit Growth Aided By Newly Acquired Nicotine Replacement Business

Dr. Reddy's Q3 FY2025 revenue reached $977 million, up 16%, with $165M net income. Growth fueled by NRT portfolio and global generics expansion.

Vandana Singh

© 2026 Benzinga | All Rights Reserved